Kory Schuh
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Attention Deficit Hyperactivity Disorder, Opioid Use Disorder Treatment, Dementia and Cognitive Impairment Research, Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes, Schizophrenia research and treatment
Most-Cited Works
- → Once-Daily Atomoxetine Treatment for Children With Attention-Deficit/Hyperactivity Disorder, Including an Assessment of Evening and Morning Behavior: A Double-Blind, Placebo-Controlled Trial(2004)467 cited
- → Effects of Atomoxetine and Methylphenidate on Sleep in Children With ADHD(2006)209 cited
- → Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions(2015)182 cited
- → Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder(2009)173 cited
- → Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity Disorder(2009)142 cited
- → Desire to smoke during spaced smoking intervals(1995)132 cited
- → Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia(2013)129 cited
- → Effects of buprenorphine and methadone in methadone-maintained subjects(1995)123 cited
- → Validation of the Adult ADHD Investigator Symptom Rating Scale (AISRS)(2009)110 cited
- → Caffeine reinforcement: the role of withdrawal(1997)99 cited